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Introduction
Treating metastatic breast cancer patients has become increas-
ingly complex, in part due to the large number of therapeutic 
options in the second- and third-line settings. Tumor heteroge-
neity imparts another key challenge for breast cancer therapy, 
especially in those tumors that become resistant to standard ther-
apies in the metastatic setting. Human epidermal growth factor 
receptor 2 (HER2), estrogen receptor (ER), and progesterone 
receptor (PR) are the main tumor targets in breast cancer and 
guide most treatment decisions; however, lack of these receptors 
or resistance to ER/PR or HER2 targeting are major therapeutic 
problems. Previous studies have shown that the expression of 
molecular markers currently used to determine anti-HER2 treat-
ments and endocrine therapy do not tend to vary in the majority 
of patients between the primary and metastatic tumors (1). For 
this reason, additional molecular alterations need to be identified 
in order to better explain tumor progression changes occurring 
during the metastatic process.
Breast cancers can be molecularly classified into 5 main 
intrinsic subtypes (basal-like, luminal A, luminal B, HER2- 
enriched [HER2E], and a normal-like group) (2, 3). We previously 
reported that the intrinsic molecular subtypes of breast cancer are 
also broadly maintained during metastatic progression; however, 
some luminal tumors are an exception (4). Existing data identify 
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High FGFR4 expression and the HER2E subtype. To test the relation-
ship of FGFR signaling pathway activity to genomically defined 
intrinsic subtypes, we characterized the distributions of FGFR 
family members across all breast cancers and their somatic genetic 
alterations. We quantified mRNA expression of each FGFR family 
member (FGFR1–4) across all breast cancer subtypes in 3 inde-
pendent data sets: The Cancer Genome Atlas (TCGA) (Figure 
1A), METABRIC (Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI130323DS1), and MD Anderson Cancer Center (MDACC) 
(Supplemental Figure 1B). TCGA patients were classified into 
PAM50-defined subtypes and each subtype into 2 immunohisto-
chemistry (IHC) subgroups according to clinical HER2 pathology 
report (cHER2+ and cHER2–). Next, we characterized the genetic 
and transcriptomic landscape of FGFR family members by sub-
type. FGFR4 mRNA expression was significantly higher in the 
HER2E subtype compared with FGFR1–3, and was independent of 
HER2 status, having high expression in both cHER2+ and cHER2– 
in all 3 data sets (Figure 1A and Supplemental Figure 1, A and B); 
FGFR4 was also mainly expressed in HER2E tumors. Conversely, 
FGFR2 and FGFR3 were mainly expressed in luminal/ER+ tumors, 
and basal-like cancers showed low mRNA expression of all 4 
FGFRs. TCGA data offered the opportunity to study the genetic 
alterations of breast cancer patients and we determined that the 
overexpression/high expression of FGFR4 is not driven by DNA 
copy-number status (Figure 1B); FGFR4 amplification/deletions 
and mutations were rare and were not correlated with high FGFR4 
mRNA expression. Finally, we tested the mRNA levels of FGFR4 
in normal breast tissue using TCGA data. FGFR4 expression 
levels were significantly higher in all tumor molecular subtypes 
compared with normal breast samples (Supplemental Figure 1C). 
Taken together, these data demonstrate that FGFR4 is unique 
among FGFR family members in its apparently nongenetically 
determined expression pattern across breast cancer subtypes, 
with high expression in HER2E genomic subtype tumors.
FGFR4 inhibitor treatment of a HER2E/cHER2– patient-derived 
xenograft. To determine if FGFR4 is a driver in HER2E-subtype 
tumors, we tested 2 possible druggable targets in HER2E/cHER2– 
tumors, namely FGFR4 itself and HER2. To model human breast 
cancer, we used NSG mice bearing an endocrine-resistant FGFR4+ 
patient-derived xenograft (PDX) model called WHIM11. WHIM11 
is of the HER2E subtype and was originally described as cHER2–, 
EGFR–, and ER+ (Supplemental Figure 2, A and B, and Supple-
mental Table 1) and thus reflects those cases of human breast 
cancer where FGFR4 is highly expressed in a nongenetic fashion 
(20, 21). However, we observed some HER2 protein expression 
in this model based on IHC assay using anti-HER2 CB11 anti-
body (the FDA-approved antibody for HER2 detection) compared 
with other PDXs considered cHER2+ (WHIM35 and WHIM8) 
or cHER2– (WHIM30 and WHIM2) (Supplemental Figure 2B). 
To target FGFR4 or HER2, we used a selective and irreversible 
FGFR4 inhibitor (BLU9931) (22), and a dual reversible inhibitor 
of HER2 and EGFR (lapatinib) (23); we note here that the efficacy 
of lapatinib in a group of patients with HER2E/cHER2– disease 
has been demonstrated via retrospective analysis (24). The doses 
of BLU9931 assessed were 0.3 and 0.6 g/kg/day as previously 
Figure 1. Comparative genetic and transcriptomic analysis of FGFR4 
family members in TCGA. (A) Box-and-whisker plots of FGFR family gene 
expression levels by mRNAseq according to molecular subtype and HER2 
status by IHC. Tumors without clinical data for HER2 status and nor-
mal-like samples have been removed from the analysis, resulting in 1028 
patients. Box-and-whisker plots display the median value on each bar, 
showing the lower and upper quartile range of the data and data outliers. 
The whiskers represent the interquartile range. Comparison between 
more than 2 groups was performed by ANOVA. Statistically significant 
values are highlighted in red. Each mark represents the value of a single 
sample. (B) Oncoprint diagram depicting high mRNA gene expression, DNA 
copy-number alterations, and mutations of FGFR family genes. *FGFR 
mRNA, high expression: high expression of genes was considered where 
levels exceeded the third quartile of positive values of gene expression 
(normalized, log2-transformed, and median-centered RNAseq data). Puta-
tive copy-number calls on 1077 cases were determined using GISTIC 2.0 
(84). Deep deletion: –2 (homozygous deletion); amplification: 2 (high-level 
amplification). Mutation types are defined only as missense mutations 
(single base pair) or truncating mutations (multiple base pairs). HER2 
clinical status was defined as previously described (85). LumA, luminal A; 
LumB, luminal B.
a subset of primary luminal/ER+ breast cancers that lose some of 
their luminal features and become more HER2E subtype–like in 
the metastatic setting (4, 5). This implies that the molecular driv-
ers involved in this specific subtype switching may also represent 
crucial promoters of metastatic progression. The HER2E subtype 
can be divided into those that are clinically HER2+ (cHER2+) or 
cHER2–, and also those that are ER+ and ER–, thus showing sig-
nificant clinical heterogeneity within a single genomic subtype. 
Targeting HER2 is a landmark in the era of precision medicine 
and several drugs have been developed to treat cHER2+ tumors 
(6–9), but how best to treat the HER2E/cHER2– tumors is much 
less established. For this reason, we have been searching for 
possible druggable targets in HER2E/HER2– tumors. Within the 
HER2E subtype (including both cHER2– and cHER2+, and ER+ and 
ER–), fibroblast growth factor receptor 4 (FGFR4) is ubiquitously 
expressed and is a possible candidate driver gene of this subtype 
beyond HER2 itself (4). FGFR4 is a tyrosine kinase (TK) receptor 
involved in proliferation, survival, and migration during embry-
onic development. In adults, it contributes to tissue homeostasis, 
as well as tissue repair, angiogenesis, and inflammation (10, 11). 
FGFR4 is highly expressed in distinct cancer types (12–15) and 
also presents genetic variants such as the FGFR4 Arg388 poly-
morphism (16–19) in rare cases. Further, the molecular function 
and kinase domain of FGFR4 differs from other FGFRs, suggest-
ing it may have a unique role when compared with them (10, 11). 
Despite these basic observations, the impact of FGFR4 on tumor 
progression in breast tumors remains poorly understood.
Importantly, we confirmed that FGFR4 is highly expressed in 
the HER2E subtype and in those tumors that acquire this HER2E 
state in the metastatic setting (4). As a result, we hypothesized that 
FGFR4 activation may represent a mechanism for subtype switch-
ing of a luminal primary tumor to a HER2E metastatic one. Here, 
we use therapeutic FGFR4 inhibition, genetic manipulations, pro-
tein kinome profiles, and single-cell RNA sequencing (scRNAseq) 
data to understand how FGFR4 alters molecular profiles, and to 
identify new possibilities for treatment options for primary and 
metastatic tumors in breast cancer.

entiation score); we constructed a model having luminal A versus 
HER2E as the axis of separation, and call this the “luminal tumor 
score” (LTS). This method allows us to calculate a relative score 
of segregation between luminal A and HER2E regardless of the 
experimental platform or models used (see Methods). The LTS is 
based on TGCA breast cancer data and compared with untreated 
and treated WHIM11 tumors (BLU9931 or lapatinib); WHIM11 
tumors treated with BLU9931 showed a significantly higher LTS 
(more luminal-like) compared with the untreated (P < 0.001) or 
lapatinib-treated (P < 0.001) tumors (more HER2E-like) (Figure 
2D). This result suggests that genes initially repressed by the activ-
ity of FGFR4 were those related to luminal tumor phenotypes.
Characterization of FGFR4-derived gene expression signa-
tures. To further characterize FGFR4 activity, we compared 
gene expression profiles between control and BLU9931-treated 
WHIM11 tumors. We performed a 2-class significance analysis of 
microarrays (SAM) (31) using a false discovery rate (FDR) of 1% 
(32, 33). This identified 745 upregulated genes that were initially 
repressed by the activity of FGFR4 before BLU9931 treatment 
(referred to hereafter as the FGFR4-repressed signature), and 427 
downregulated genes that were positively regulated by FGFR4 
activity before treatment (FGFR4-induced signature). The 
FGFR4-induced signature contained proliferation genes such as 
E2F1, CCNB2, CDC6, ORC6, and POLE2, survival-related genes 
including MET and PRKCA, genes related to epithelial-mesenchy-
mal transition (EMT) including ITGB5, CXCL1, and COL4A2, and 
genes involved in subtype differentiation such as KRT19, KRT16, 
and ITGA6 (also known as CD49f) (Supplemental Table 2). Con-
versely, the FGFR4-repressed signature contained many known 
luminal subtype–related genes also involved in mammary gland 
development such as ESR1, FOXA1, GBLI3, PRLR, BCL2, and 
ERBB4 (Supplemental Table 2).
Next, each FGFR4-associated gene set was hierarchically 
clustered across 1100 breast tumors and 98 normal samples from 
TCGA data set (Figure 2, E and F) representing all 5 subtypes of 
breast cancer. We identified multiple distinct gene clusters and 
by examining Gene Ontology (GO) we considered each cluster 
to represent a different FGFR4-associated biological signature. 
Gene cluster associations with GO for the FGFR4-induced sig-
nature were as follows: ligand-binding receptor and protein phos-
phorylation (cluster 1), tissue epithelium development (cluster 2), 
protein localization and transport (cluster 3), cell cycle and prolif-
eration (cluster 4), and chemical reactions and pathways involving 
monocarboxylic acids or oxidation-reduction processes (cluster 
5) (Figure 2E and Supplemental Table 3). In order to differentiate
changes derived from FGFR4 activity from those directly related
to inhibition of cell proliferation caused by FGFR4 inhibition, the
gene set known to be associated with proliferation (34–36) was
removed from the FGFR4-induced signature from this point for-
ward (cluster 4). Hallmark gene set enrichment analysis (34) of the 
entire-gene FGFR4-induced signature list revealed that this was
enriched for genes involved in STAT3, PI3K/AKT/mTOR pathway, 
and KRAS activation, hypoxia, glycolysis, EMT, and genes encod-
ing components of apical junctions (Supplemental Table 5).
Clustering of the FGFR4-repressed signature genes revealed 
4 unique clusters. GO analysis revealed that these genes were 
related to development or immune system function (cluster 1); 
 
Figure 2. Testing the impact of FGFR4 on tumor growth and tumor 
differentiation in a HER2E/cHER2– PDX (WHIM11). (A) Tumor growth and 
(B) tumor weight of WHIM11 tumors treated with BLU9931 (0.6 g/kg/day) 
or lapatinib (1.833 g/kg/day) for approximately 18 days (5 animals per 
treatment arm). Data represent mean tumor volume ± SEM. (C) Correla-
tion to the PAM50 centroids (basal, HER2E, luminal A, luminal B) of mice 
treated with BLU9931 and untreated mice. (D) BLU9931-treated, lapa-
tinib-treated, or untreated tumors evaluated for a luminal tumor score 
(LTS) tested along with TGCA cohort grouped according to intrinsic 
subtype. (E and F) Supervised hierarchical cluster across 1100 breast 
tumors and 98 normal samples from TCGA data set using FGFR4-related 
signatures. Significantly upregulated genes defined as an FGFR4- 
repressed signature (E) and significantly downregulated genes defined 
as a FGFR4-induced signature (F). Each gene set or subcluster has been 
selected based on a node correlation greater than 0.5 and named accord-
ing to the important biological process governed by it as identified by 
Gene Ontology. Comparison between more than 2 groups was performed 
by ANOVA with post hoc Tukey’s test: *P < 0.05; **P < 0.01; ***P < 0.001. 
Statistically significant values are highlighted in red. Box-and-whisker 
plots display the median value on each bar, showing the lower and upper 
quartile range of the data. The whiskers represent the interquartile range.
described (22) for a period of 4 weeks; we observed that neither 
dose induced weight loss or other signs of significant toxicity, and 
we thus treated the mice with 0.6 g/kg/day. For lapatinib, we used 
the same dose (1.833 g/kg/day) that we previously described (20, 
25, 26). Tumor volume (Figure 2A) and tumor weight (Figure 2B) 
were significantly reduced in WHIM11 tumor–bearing mice treat-
ed with BLU9931 or lapatinib (all P < 0.01) for 18 days.
FGFR4 as a potential driver of tumor dedifferentiation. We and 
others have hypothesized that the intrinsic subtypes of breast 
cancer recapitulate the normal breast epithelial differentiation 
hierarchy axis (mammary stem cell→luminal progenitor cells→-
mature luminal cells) (27, 28). We previously developed a tran-
scriptome-defined differentiation score based on purified mam-
mary epithelial cell populations (29). The intrinsic molecular 
subtypes can be ordered according to their differentiation score 
where the claudin-low-subtype tumors are the least differenti-
ated and most like mammary stem cells, followed by basal-like 
tumors that are the most like luminal progenitor-like, followed 
by HER2E and then luminal A/B that are the most differentiated 
and closest to mature luminal cells (29). We hypothesized that 
FGFR4 could be an important driver of shifts between subtypes 
and among this differentiation hierarchy. To test this, we col-
lected gene expression data of untreated and BLU9931-treated 
WHIM11 tumors and calculated the correlation of each to the 
PAM50 subtype centroids (30). WHIM11 tumors treated with 
BLU9931 were significantly more similar to the luminal A sub-
type and less HER2E, luminal B, or basal-like compared with the 
control group (Figure 2C). Although lapatinib treatment signifi-
cantly decreased the tumor growth of WHIM11, no significant 
change was found by comparing the PAM50 centroids before 
and after treatment (Supplemental Figure 3A), showing that inhi-
bition of FGFR4 activity affected subtype differentiation status 
in this model, while HER2 inhibition did not.
Next, in order to find a better alignment with tumor-intrinsic 
subtype differentiation status, we developed a transcriptional phe-
notype score based on similarity to tumor subtypes (as opposed to 
similarity to normal epithelial cells for the aforementioned differ-
mammary gland development, morphogenesis of epithelial tubes, 
and estrogen response signaling (cluster 2); ribosome-related 
genes and protein targeting (cluster 3); and chromatin modifi-
cation and regulation of transcription (cluster 4) (Figure 2F and 
Supplemental Table 4). Hallmark gene set enrichment analysis 
(34) of the entire gene list showed that this signature was enriched 
for genes involved in bile acid metabolism, genes downregulated
by KRAS signaling, genes overrepresented on the apical surface
Figure 3. Testing FGFR4-associated signatures in genetically engineered or chemically inhibited breast cancer cell lines. (A) Box-and-whisker plots 
depicting the Euclidean distance of each group of cell lines to the UNC337 tumor-intrinsic subtypes. Lower Euclidean distance suggests higher similarity 
to the subtype call. (B) Analysis of luminal tumor score (LTS) in each cell line tested along with TCGA grouped according to intrinsic subtype. (C) Average 
expression (signature score) of FGFR4-induced signature and FGFR4-repressed signature of each cell line described in A and B. Comparisons between 2 
groups were performed by 2-tailed t test. Comparison between more than 2 groups was performed by ANOVA. Box-and-whisker plots display the median 
value on each bar, showing the lower and upper quartile range of the data and data outliers. The whiskers represent the interquartile range. Each mark 
represents the value of a single sample. Statistically significant values are highlighted in red.
 
important for cell polarity, genes related to the p53 pathway, genes 
related to peroxisomes, and genes upregulated in response to 
IFN-γ and TGF-β (Supplemental Table 5).
Proteomic profiling of the FGFR4 kinome in a PDX. To further 
characterize the role of FGFR4 in WHIM11, we quantitatively 
measured the dynamic changes in kinase activity using multi-
plexed inhibitor beads coupled with mass spectrometry (MIB/
MS) (37–39). We profiled the kinome of WHIM11 tumors treated 
with BLU9931 for 18 days and then released from this inhibition 
for 14 days, to identify those kinases that were induced upon 
removal of the drug; 258 kinases were detected in total. We next 
used 2-class SAM (31) with an FDR of 5% to identify proteins 
with significantly different levels (Supplemental Table 6); after 
BLU9931 treatment, 41 kinases were significantly reduced and 
54 were upregulated where FGFR4 was the most significantly 
repressed kinase (Supplemental Table 6). After drug removal, 28 
kinases were significantly induced and 46 repressed, and again 
FGFR4 had the most dramatically changing protein levels (Sup-
plemental Table 6). These protein data were hierarchically clus-
tered, and as expected, a significant portion of these patterns 
was associated with proliferation and decreased with treatment 
and induced upon drug removal (Supplemental Figure 4A). The 
51 commonly affected kinases after BLU9931 treatment and 
expressed again after drug removal describe the reactivation of 
the FGFR4 pathway and are represented in Supplemental Fig-
ure 4B, grouped by 11 different families of kinases. In addition to 
FGFR4, the main induced kinases after drug removal were pro-
liferation-related groups including NEK (NEK2), CAMK group 
(MELK), CMCG group (CDK1 and CDK13), and the Aurora fam-
ily (AURKA and AURKB). Other induced kinases included some 
involved in mRNA splicing from the CMCG group (SRPK1 and 
CLK1) and some involved in controlling growth and differenti-
ation like the ACG group (RPS6KA4, RPS6KA1, and RPS6KA3). 
Importantly, this result shows how BLU9931 dampened FGFR4 
activity while other TK-family receptors remained relatively 
unchanged (only EPHA2 decreased in a small proportion), thus 
demonstrating that BLU9931 exhibited limited off-target effects 
on the TK-family receptors analyzed (Supplemental Figure 4B). 
Finally, we note that a portion of these kinases (CHUK, MELK, 
ZAK, RPS6KA4, RPS6KA3, PLK1, PLK4, AURKB, PKMYT1, HK2, 
and PRKAA2) were also identified in our gene expression analysis 
of FGFR4 signaling in WHIM11 tumors (Supplemental Figure 4C 
and Supplemental Table 6).
Validation of FGFR4-associated signatures in breast cancer cell 
lines. To test if ectopic expression/activation of FGFR4 alters dif-
ferentiation status in established breast cancer cell lines, we used 
lentiviral particles containing the FGFR4 gene to transduce 2 
luminal breast cancer cell lines, MCF7 and T47D (both HER2–FG-
FR4loER+; see Methods section, Supplemental Table 1, and Sup-
plemental Figure 6, A and B for FGFR4 protein quantification). In 
addition, we obtained 2 cell lines with high levels of FGFR4 activ-
ity: the MDA-MB-453 luminal cell line (FGFR4hiHER2+ER–) that 
has a known activating mutation in FGFR4 (40) and the luminal 
cell line CAMA-1 (FGFR4+HER2–ER+) (Supplemental Figure 5A). 
The experimental conditions for gene expression analysis are sum-
marized in Supplemental Figure 5, A and B (at least 4 replicates 
for each cell line). We treated the FGFR4-active cell lines (MDA-
MB-453 and CAMA-1) with BLU9931 at their IC50 doses (Supple-
mental Figure 6C) to identify FGFR4-regulated genes, and at the 
same time identified the sets of genes induced upon introduction 
of FGFR4 into the 2 FGFR4lo luminal/ER+ cell lines (MCF7 and 
T47D). The overall gene expression patterns of each cell line was 
then compared to each PAM50 tumor subtype using the Euclidean 
distance to each PAM50 subtype centroid, which showed that the 
FGFR4-active group (i.e., CAMA-1 and MDA-MB-453 without 
drug, and MCF7 and T47D + FGFR4) were more similar to HER2E 
and/or basal-like tumors and less similar to luminal A tumors 
(Figure 3A). Likewise, cells overexpressing FGFR4 showed a sig-
nificantly lower LTS (more HER2E-like), and by treating those 
cells with BLU9931, they gained a significantly higher LTS (more 
luminal-like) while losing their HER2E features (Figure 3B).
We also tested the WHIM11-derived FGFR4 signatures 
(induced and repressed). As expected, the FGFR4-activated cell 
lines had higher expression of the FGFR4-induced signature, 
and conversely, the FGFR4-repressed signature was enriched in 
cell lines with blocked FGFR4 activity (Figure 3C). Given recent 
reports that FGFR4 may impact endocrine resistance (41), we 
tested if expressing high levels of FGFR4 could lead to estrogen- 
independent growth using 2 luminal/ER+ breast cancer cell lines. 
MCF7-FGFR4+ and T47D-FGFR4+ cells presented higher cell 
viability compared with empty vector–transfected controls after 
6 days of estrogen deprivation (Supplemental Figure 6E). Thus, 
FGFR4 activation may facilitate departure from luminal-like 
programming toward HER2E by facilitating independence from 
hormone receptor signaling.
As a second FGFR4-targeting approach, we used the CRISPR 
genome editing system to genetically inactivate FGFR4; howev-
er, we performed CRISPR/Cas9 on MDA-MB-453 and CAMA-1 
cell lines and we were not able to obtain a homozygous knockout 
clone. According to the estimation of cancer gene dependencies 
from a large-scale RNAi screen published by McFarland et al. (42), 
FGFR4 is an essential gene in MDA-MB-453 and CAMA-1 cell 
lines measured by the DEMETER2 method (42). MDA-MB-453 
and CAMA-1 cell lines have one of the highest FGFR4 gene depen-
dency scores compared with a panel of breast cancer cell lines, in 
accordance with a higher FGFR4 gene expression (Supplemen-
tal Figure 6D), which we believe explains the inability to obtain 
CRISPR double-knockout clones.
Analysis of subtype switching using scRNAseq on WHIM11. To 
precisely determine if the shift between subtypes represents 
an example of cellular plasticity under the selective pressure of 
BLU9931 treatment, or alternatively is due to clonal selection, 
we performed 2 different genomic experiments. First, we used 
whole-exome sequencing to compare DNA markers of clonality 
in untreated and BLU9931-treated WHIM11 tumors that were 
allowed to regrow after removal of BLU9931 for 2 weeks. A super-
vised analysis using the 31 mutations described in WHIM11 in Li 
et al. (ref. 21 and Supplemental Table 7) showed a very high cor-
relation between the variant allele frequency (VAF) of untreated 
WHIM11 tumors and BLU9931-treated and released tumors 
(Pearson’s r = 0.97, P < 0.001) (Supplemental Figure 7A). Simi-
lar results were found when we compared our WHIM11 tumors 
with the original WHIM11 from Washington University published 
in 2013 (21) (Pearson’s r = 0.83, P < 0.001) (Supplemental Figure 

8), we did not consider this cluster for further expression score 
quantification. By comparing all cells of each experimental group, 
the average expression of FGFR4 was significantly lower, and that 
of ERBB2 and ESR1 significantly higher, for the BLU9931-treated 
group, supporting the bulk-tumor gene expression arrays (Supple-
mental Figure 7H).
We also employed the previously developed FGFR4 signa-
tures and the LTS in the scRNAseq data. The FGFR4-induced 
signature was lower in cluster 0 but higher in clusters 1, 2, and 
5 (Figure 4C and Supplemental Figure 8D). FGFR4-repressed 
signature was higher in cluster 0 (Figure 4E and Supplemental 
Figure 8E). Proliferation signature score showed that highly pro-
liferative cells decreased after BLU9931 treatment (clusters 2 and 
5) (Figure 4G and Supplemental Figure 8F), and rebounded upon 
drug removal. The LTS showed that cluster 0 was the most lumi-
nal A–like cell population, while clusters 2 and 5 were the most
HER2E-like (Figure 4I and Supplemental Figure 8G). Clusters 1
and 4 were a mixture of FGFR4-induced and -repressed signa-
tures as well as HER2E and luminal A phenotypes (Figure 4, C,
E, and I, and Supplemental Figure 8, D, E, and G). The average
expression of the signatures depicted in Figure 4, C, E, G, and
I, and grouped by the 3 experimental groups was significantly
lower for FGFR4-induced and proliferation signatures and sig-
nificantly higher for the FGFR4-repressed signature and LTS in
the BLU9931-treated group (Supplemental Figure 8I). Together,
these data suggest that BLU9931 treatment does not have selec-
tive activity on specific subclones within WHIM11 tumors, but
rather acts on all cells, with alterations in expression profiles sup-
porting dynamics in cellular plasticity.
FGFR4-derived gene signatures are associated with multiple clin-
ical features. To further understand the FGFR4-associated in vivo 
phenotypes in breast cancer patients, both FGFR4 signatures were 
used to determine a gene signature score calculated as the mean 
expression value for all genes in a signature, calculated for each 
patient in TCGA data set. This analysis showed that the FGFR4- 
induced signature was highly expressed in the HER2E-subtype 
tumors, but also in basal-like tumors (Figure 5A). Conversely, the 
FGFR4-repressed signature was enriched in luminal A tumors 
(Figure 5A). In addition, we included histologic subtypes (i.e., 
invasive lobular carcinoma [ILC], invasive ductal carcinoma 
[IDC], and mixed [ILC+IDC]) in the molecular subtyping classifi-
cation (49) as a separate group, where the FGFR4-repressed signa-
ture was high in ILC tumors (Supplemental Figure 3C).
To further test if these 2 FGFR4 signatures are robust dis-
criminators of tumor differentiation, we calculated the correla-
tion between the 2 FGFR4 signatures and the LTS using TCGA 
data set. The FGFR4-induced signature negatively correlated 
with LTS (Pearson’s r = –0.4588, P = 2.082 × 10–63) (Figure 5B), 
while the FGFR4-repressed signature showed a positive correla-
tion with the LTS (Pearson’s r = 0.8318, P = 5.717 × 10–308) (Figure 
5B). To further test if either FGFR4 signature was associated with 
the pathological measure of tumor differentiation (i.e., grade), 
we tested the association of FGFR4 signatures with tumor grade 
using the METABRIC cohort (1671 patients). As shown in Figure 
5C, the FGFR4-induced signature was associated with high grade 
(Figure 5C), while the FGFR4-repressed signature was associated 
with low grade (Figure 5C).
Figure 4. Single-cell RNA sequencing of WHIM11 tumor treated with 
BLU9931 and drug released. (A) Left panel: Uniform manifold approxima-
tion and projection (UMAP) plot of all combined cells (30,058 cells in total) 
that passed quality checks in untreated WHIM11 (n = 2; 9298 cells), treated 
with BLU9931 (n = 2; 9777 cells) (0.6 g/kg/day) for 14 days, and treated but 
released of drug for 18 days (n = 2; 10,983 cells). Cells and clusters are color 
coded by each cell population found. Right panel: Heatmap of significantly 
differentially expressed genes and main Gene Ontology annotations for 
each cluster in WHIM11 based on MSigDB. Significant genes were identified 
by Wilcoxon’s signed-rank t test. (B) UMAP plot of all the cells that passed 
quality checks in WHIM11 and divided by each experimental condition as 
untreated, treated with BLU9931 (0.6 g/kg/day) for 14 days, and treated 
but released of drug for 18 days. Cells and clusters are color coded by each 
cell population found. (D, F, and H) UMAP plots showing the expression 
of FGFR4, ERBB2, and ESR1 genes across all WHIM11 clusters in WHIM11 
untreated, treated with BLU9931 (0.6 g/kg/day) for 14 days, and treated  
but released of drug for 18 days. (C, E, G, and I) UMAP plots showing 
the gene signature score (average values of genes present in each score 
respectively for each cell) of FGFR4-induced signature, FGFR4-repressed 
signature, proliferation signature, and luminal tumor score (LTS) across all 
WHIM11 clusters in WHIM11 untreated, treated with BLU9931 (0.6 g/kg/
day) for 14 days, and treated but released of drug for 18 days.
6B). Thus, from a DNA marker perspective, BLU9931 treatment 
did not alter tumor clonality.
Next, we performed scRNAseq analysis on the untreated,  
14-day BLU9931-treated, and 14-day BLU9931-treated and 
drug-released WHIM11 tumors to further examine intratumor het-
erogeneity. Analysis of resulting transcriptomic data using the Seur-
at package (https://satijalab.org/seurat/) identified 8 different cell 
subpopulations in WHIM11 tumors (Figure 4A). Major biological 
terms enriched in these groups were identified using MSigDB (refs. 
43, 44 and Supplemental Table 8). FGFR4, ERBB2, and ESR1 genes 
were expressed in all cell clusters. Cluster 0 was enriched for lumi-
nal-like features including cell differentiation and cell-cell adhesion 
terms, and showed high expression of ERBB2 and ESR1 (Figure 4, B, 
F, and H, and Supplemental Figure 8, B and C). In addition, cluster 
0 had lower expression of FGFR4, and was mainly present in the 
BLU9931-treated group (Figure 4, B–D, and Supplemental Figure 
8A). Moreover, clusters 3 and 6 were mainly seen after drug release. 
These clusters were related to translational initiation and glycolysis, 
respectively, probably in response to nutrient availability and mito-
genic stimulation after drug release (Figure 4A and Supplemental 
Table 8). Clusters 2 and 5 were enriched in G2/M phase– or S phase–
specific genes (45), respectively (Figure 4A, and Supplemental Table 
8). Clusters 1 and 4 were similar and enriched in the untreated and 
released experimental groups and had higher FGFR4 gene expres-
sion values linked to cell adhesion and regulation of gene expres-
sion, respectively (Figure 4, A and D, and Supplemental Table 8). 
Interestingly, cluster 7 was formed by a small number of cells (25 
cells) and enriched in treated samples only; the gene expression 
pattern of cluster 7 was very specific and related to cilium organiza-
tion and cell projection (see genes in Supplemental Table 8). Deple-
tion of proliferation-related genes in treated tumors like NEK2 and  
AURKA, as demonstrated through proteomic profiling (Supple-
mental Figure 4B), were closely related to cilia formation in breast 
cancer (46, 47) and growth factors like FGF contribute to their 
resorption (48). Based on the lower number of cells present in clus-
ter 7 compared with the rest of the clusters (Supplemental Table

type information) (Supplemental Table 1). We first determined the 
distribution of the PAM50-intrinsic subtypes across this cohort 
(Supplemental Figure 9E and Supplemental Table 1). This allowed 
us to avoid the possible confounding factor of intrinsic subtype 
in the subsequent analysis, as we divided tumors into 2 data sets 
based on the subtype of the primary tumor from each pair: a 
“luminal set” comprising all luminal A/B– and HER2E-subtype 
patients (77 pairs) (Supplemental Figure 9A) and a “basal-like 
set” containing 8 basal-like–only pairs (Supplemental Figure 9B); 
samples (and the pair) called normal-like in either the primary or 
metastatic tumors were removed from the analysis (Supplemen-
tal Figure 9, A, B, and D). The subtype discordance rate between 
primary and metastatic tumors in the luminal data set (Supple-
mental Figure 9A) and the entire data set (Supplemental Figure 
9C) showed that luminal A tumors had the highest discordance 
rate and often changed to luminal B or HER2E (37.5% and 15%, 
respectively), which is in agreement with previous results (4). The 
basal-like subtype was maintained in all samples as basal-like 
(100%) (Supplemental Figure 9B), and only 2 HER2E primary 
tumors were called basal-like in the metastases (16.6%); the sites 
and number of metastases are summarized in Supplemental Fig-
ure 9F and Supplemental Table 1.
We next performed a supervised 2-class paired analysis to iden-
tify genes significantly upregulated in metastasis. From luminal 
A/B and HER2E tumors (luminal set), we detected 119 upregulated 
and 487 downregulated genes in metastatic tumors at an FDR of 
0. FGFR4 was the only FGFR family member significantly upreg-
ulated and was among the highest differentially expressed genes.
Analyzing our primary and metastatic paired samples, 13% of all
primary tumors had high expression of FGFR4 considering all sub-
types, and 60% of all HER2E subtype tumors had high expression
of FGFR4 by mRNA (FGFR4 mRNA expression was considered
high expression when it was greater than 75% of positive values in
RNAseq median-centered data) (Supplemental Figure 9G).
Other key genes expressed in luminal tumors and typically 
associated with a better prognosis including PGR, ESR1, BCL2, 
SLC39A6, GATA3 and NAT1 were downregulated in luminal 
tumor metastases, suggesting that the majority of the metastatic 
tumors were losing luminal properties. Genes significantly higher 
in luminal metastases beyond FGFR4 included PTTG1, BIRC5, 
CCNB1, CDC6, and AURKA; these genes are associated with 
proliferation and cell cycle processes (Supplemental Table 9), 
and were highly expressed in luminal B and HER2E compared 
with luminal A tumors. Genes related to the HER2E subtype (35, 
50–53), neutrophils, monocytes, and myeloid-derived suppressor 
cells (MDSCs) (54–56) such as S100A9, S100A8, and others like 
TDO2 (57, 58), were also upregulated in metastases compared 
with primary tumors (Supplemental Table 9).
Basal-like tumors showed many fewer differences in gene 
expression than luminal paired tumors, resulting in only 5 genes 
(RN7SL314P, ZBTB8B, PKMP3, NYAP1, and METTL21EP) 
demonstrating significant changes (Supplemental Table 9). To 
test whether differentiation states are altered between primary 
tumors and paired metastases, we calculated the LTS in the lumi-
nal paired tumors and determined that it was significantly lower in 
metastases compared with the primary tumors (Figure 6A). To test 
the association of FGFR4 activity with this process, we next tested 
Figure 5. Prognostic value of FGFR4-derived signatures. (A) Average 
expression of FGFR4-related signatures in TCGA tumor molecular sub-
types. Normal-like patients and true-normal tissues have been removed 
from the analysis. Statistical differences were calculated by ANOVA test. 
(B) Scatterplot showing the correlation between FGFR4-related signatures 
and luminal tumor score (LTS) (as calculated in TCGA data set using only 
HER2E, luminal A, and luminal B tumors). Correlation was measured using 
the Pearson correlation coefficient. (C) Average expression of FGFR4-
related signatures depending on histological tumor grade in METABRIC 
data (Grade 1: Low grade or well differentiated; Grade 2: Intermediate grade 
or moderately differentiated; Grade 3: High grade or poorly differentiated). 
(D and E) Kaplan-Meier plots to test the prognostic ability of FGFR4 signa-
tures in METABRIC (D) and MDACC (E) data sets (normal-like samples were 
removed from the analysis in both cohorts). Survival curve differences were 
calculated by the log-rank test and the estimates of survival probabilities 
and cumulative hazard with a univariate Cox proportional hazards model. 
(F) Multivariable Cox proportional hazards analyses using METABRIC data 
(normal-like samples were removed from the analysis). Hazard ratio (HR) = 
1: no effect. HR < 1: reduction in hazard. HR > 1: increase in hazard. Signa-
tures were evaluated as continuous variables and rank ordered according 
to the gene FGFR4 signature scores (induced and repressed) in 3 different 
levels: low, medium, and high (assigned by distribution in a given upper, 
middle, or lower tertile). Comparison between more than 2 groups was 
performed by ANOVA. Statistically significant values are highlighted in red. 
Box-and-whisker plots display the median value on each bar, showing the 
lower and upper quartile range of the data and data outliers. The whiskers 
represent the interquartile range. Each mark represents the value of a 
single sample. LumA, luminal A; LumB, luminal B.
Next, we tested the prognostic ability of the FGFR4 signa-
tures in the METABRIC data set (Figure 5D) and MDACC breast 
cancer data set (477 patients) (Figure 5E). For this analysis, we 
rank ordered the patients into tertiles according to their FGFR4- 
induced and FGFR4-repressed signature scores. As demonstrated  
by Kaplan-Meier analysis, both FGFR4 signatures were signifi-
cantly associated with overall survival (OS). Patients with a high 
FGFR4-induced signature had a lower OS rate (HR = 6.299, P = 
3.07 × 10–12, CI = 3.76−10.6) (Figure 5D) and patients with a high 
FGFR4-repressed signature presented better prognosis (HR = 
0.3251, P = 1.17 × 10–9, CI = 0.226−0.467) (Figure 5D). Additionally, 
high scores of the FGFR4-repressed signature were strongly asso-
ciated with a lower distant recurrence–free survival (DRFS) (HR 
= 0.01668, P = 7.32 × 10–8, CI = 0.00376–0.074) (Figure 5E) and 
FGFR4-induced signature with a higher DRFS (HR = 13.39, P = 1.42 
× 10–3, CI = 2.72−66) (Figure 5E). A multivariate analysis using the 
METABRIC data set and the covariates of PAM50 subtypes, ER and 
PR status, and histological grade and tumor stage showed that the 
FGFR4-induced signature (HR = 2.41, P = 1.0 × 10–2, CI = 0.01−4.65) 
was a significant independent prognostic factor (Figure 5F).
Transcriptome comparison between primary and paired metastatic  
tumors. Previous work by our group using a panel of 105 genes 
showed that FGFR4 was one of the top genes highly expressed 
in metastasis compared with the matched primary tumors (4). To 
further define a possible role for FGFR4 in metastasis, we assayed 
103 primary tumor–metastasis pairs using RNAseq and tested our 
FGFR4 signatures alongside hundreds of genomic signatures for 
differential expression across this breast tumor metastatic land-
scape. All tumors were assigned to an intrinsic molecular subtype 
of breast cancer using the previously reported (4) PAM50 subtype 
predictor (except 1 primary paired metastases with missing sub-
(Supplemental Figure 10, A and B). Together, these data illustrate 
that some luminal primary tumors lose luminal-like properties 
and gain enhanced FGFR4 activity concomitant with HER2E- 
subtype features in metastases.
To understand what other pathways and processes asso-
ciate with FGFR4 in established metastases, we analyzed 
696 prespecified gene expression modules (35, 59) alongside 
the newly developed FGFR4 signatures and proliferation scores in 
tumor-met pairs. Here, we found the FGFR4-induced signature 
and proliferation score were significantly higher in metastases 
compared with the primary tumors (Figure 6, B and C). Likewise, 
metastatic tumors trended toward a lower FGFR4-repressed sig-
nature score (Figure 6B). No significant result was found in basal- 
like paired samples for either FGFR4 signature or proliferation 
Figure 6. Expression profile and FGFR4-associated signatures in matched breast primary tumors and metastases. (A) Luminal tumor score (LTS) 
calculated values in 77 primary and 77 paired metastatic tumors in the luminal set. (B) Expression levels of FGFR4-induced (left) and FGFR4-repressed 
signatures (right) in 77 primary and 77 paired metastatic luminal tumors. (C) Proliferation scores for FGFR4-induced and -repressed signatures (see PAM50 
subtype classification in Methods) in 77 primary and 77 paired metastatic luminal tumors. (D) Supervised hierarchical cluster analysis derived from the 
significantly different modules scores, in luminal and (E) basal sets. Significance of the differences between modules was calculated using 2-class SAM at 
an FDR of 0%. Significantly up- and downregulated modules are clustered together for each set (basal and luminal). Clusters (4 from luminal and 5 from 
basal set) were selected based on node correlation greater than 0.5. Comparisons between 2 paired groups were performed by paired, 2-tailed t test. Sta-
tistically significant values are highlighted in red. Box-and-whisker plots display the median value on each bar, showing the lower and upper quartile range 
of the data and data outliers. The whiskers represent the interquartile range. Each mark represents the value of a single sample. LumA, luminal A; LumB, 
luminal B; PRIM, primary tumor; MET, metastatic tumor.
ure 11, A and B); this suggests that macrophage infiltration is 
associated with metastases in luminal/HER2 cancers (with 
most other immune features being unchanged). Conversely, 
modules downregulated in luminal metastasis were grouped 
in clusters 3 and 4, and composed mainly of stroma-related 
signatures, mammary stem cell (MaSC), and luminal subtype 
signatures (Figure 6D).
To further explore a possible relationship between FGFR4 
expression and genetic alterations we used the RNAseq data to 
identify mutations in FGFR4. Other studies have estimated that 
FGFR4 is mutated in 1%–3% of cases, altered at a higher rate in 
the metastatic setting (63–65). Considering only the mutations 
found in COSMIC (66, 67), we analyzed the mutation calls on 
206 samples for FGFR4 and identified 9 variants (5 primary and 
4 metastatic unpaired tumors) as being mutated (4% of cases) 
(Supplemental Table 11). Otherwise, if we consider mutations 
in COSMIC that were described only in breast cancer (63–65), a 
single primary tumor harbored an FGFR4 mutation (0.5% mutat-
ed), demonstrating again that high expression of FGFR4 is proba-
bly nongenetically determined.
Supervised analysis of the 8 paired basal-like tumors, using 
an FDR of 0, identified 3 upregulated and 51 downregulated 
modules in basal-like metastasis compared with the primary 
the new FGFR4 signatures (Supplemental Table 10) in the 77 
paired luminal and 8 paired basal-like tumors. Supervised 
analysis identified 119 upregulated modules and 43 downreg-
ulated in the luminal set (Supplemental Table 9). A supervised 
hierarchical cluster derived from the significantly differen-
tially expressed modules showed 4 main clusters of signatures 
(Figure 6D). Clustering results revealed that certain primary 
tumors and metastases were more similar, but the dominant 
trend was distinction between metastases and primary tumors. 
As expected, the FGFR4-induced signature was significantly 
higher in metastases compared with primary tumors (cluster 
1), as were proliferation signatures (Figure 6D). In addition, 
the FGFR4-induced signature demonstrated a strong relation-
ship with high expression of signatures related to proliferation, 
angiogenesis, HER2E/luminal B features, luminal progenitor 
features, and downregulation of EMT. Interestingly, we also 
found tight covariance between M2 macrophage and inflam-
matory breast cancer signatures, and the newly defined LTS 
with other signatures closely related to the HER2E subtype. 
In fact, a marker panel specific to M1 (CD68) or M2 macro-
phages (MRC1, CD163, ARG1, MERTK, and MACRO) (60–62) 
showed significantly higher expression in luminal metastases, 
but not in basal-like metastatic tumors (Supplemental Fig-
Figure 7. Univariate analysis in 855 primary tumors with known first site of relapse. Kaplan-Meier and Cox proportional hazards model analyses of 
metastasis-free survival (MFS) analyzed in their specific sites of relapse: brain (A), lymph node (B), lung (C), bone (D), liver (E), or any site of relapse (F). 
Survival curve differences were calculated by the log-rank test and the estimates of survival probabilities and cumulative hazards with a univariate Cox 
proportional hazards model. FGFR4-derived signatures were evaluated as continuous variables and rank ordered according to the gene FGFR4 signature 
scores (induced and repressed) in 3 different levels: low, medium, and high (assigned by distribution in a given upper, middle, or lower tertile). Hazard ratio 
(HR) = 1: no effect. HR < 1: reduction in the hazard. HR > 1: increase in hazard. Statistically significant values are highlighted in red.
activation state of the kinome, and the scRNAseq data demon-
strate that FGFR4 activity could be regulating tumor plasticity 
and actively repressing many genes involved in luminal tumor 
cell differentiation and inducing genes involved in the more 
proliferative and metastatic HER2-enriched phenotype. We 
demonstrated that in PDX WHIM11, FGFR4 is highly activated 
and triggers MAPK/ERK and PI3K cascades. How FGFR4 acti-
vation occurs in HER2E breast cancers is still unknown. There is 
evidence that FGFR4 is activated via binding to specific ligands, 
and can dimerize and activate in the absence of FGF ligand(s) 
through ligand-independent mechanisms (72–74); based on data 
mining of the genomics data, it is not obvious which means of 
activation is occurring. Although we hypothesize that FGFR4 
drives subtype switching, further study is needed to gain more 
insight into what is triggering FGFR4 activation.
In vitro experiments overexpressing FGFR4 in 2 luminal cell 
lines, or blocking FGFR4 activity, corroborated that FGFR4 activity is 
associated with subtype switching. Our data also suggested that cells 
genetically modified to overexpress FGFR4 were more HER2E-like 
than their counterpart controls or those treated with an FGFR4 inhib-
itor. The FGFR4-induced signature was strongly prognostic and high 
expression predicts low OS/DRFS, even in a multivariate analysis 
adjusting for subtype and multiple clinical features. Conversely, the 
FGFR4-repressed signature predicted a better prognosis.
The 77 primary tumor–metastasis pairs analyzed confirmed 
that the major differences found between primary and met-
astatic tumors were found in the luminal subset. The highest 
subtype-change rate was found from luminal A toward luminal 
B or HER2E. The newly derived LTS supported this hypothesis, 
allowing us to rank the level of differentiation between the lumi-
nal subtypes (HER2E and luminal A/B) and providing an objec-
tive means of assessing genomic-based tumor differentiation 
status within these ER+/luminal tumors. Around 40% to 50% 
of patients with luminal breast cancer experience relapses that 
include distant metastases (75, 76). Therefore, since they repre-
sent the most common subtype of the disease, luminal tumors 
are responsible for most breast cancer deaths. In clinical prac-
tice, treatment decisions are mostly based on the primary tumor 
phenotype; however, if we do not take into consideration evolu-
tion between the primary and metastatic tumor as demonstrated 
here, we may be missing a number of key therapeutically relevant 
tumor targets, including FGFR4.
Interestingly, in our study those primary tumors showing high 
luminal-like features (high LTS), mostly luminal A tumors, had 
the lowest LTS (more HER2E-like) in the metastatic site, while 
the HER2E and luminal B primary tumors remained relatively 
unchanged. These results suggested that under the influence of 
the microenvironment, treatment selection pressure, and proba-
bly with the increase/selection of cells with a higher FGFR4 activ-
ity, the more luminal A–like tumors could be more susceptible to 
change their phenotype in the metastatic setting. FGFR4 activa-
tion may promote cell proliferation and dedifferentiation, and 
ultimately tumor subtype switching, becoming a driver of metas-
tasis in these luminal tumors. We again note that this high FGFR4 
expression is not genetically driven (neither amplified nor activat-
ing mutations), and thus this key drug target will be missed when 
using DNA-based tests.
tumors (Supplemental Table 9). A second supervised cluster 
only derived from the significant modules showed 5 new clus-
ters (Figure 6E). A signature recently published by our group as 
being more highly expressed in metastases derived from a dif-
ferent data set (68) was also significantly higher here, but only 
in basal-like metastases. Clusters 2, 3, 4, and 5 were modules 
downregulated in metastatic basal-like tumors and where cluster 
2 presented a decrease in immune signatures related to effector 
CD8+ T cells and memory CD8+ T cells, B cells, monocytes, M0 
macrophages, IFN-γ and IFN-α signaling, and MDSCs (Figure 
6E, Supplemental Figure 10C, and Supplemental Table 9). No 
changes were detected for M2-like profiles or FGFR4 signa-
tures. EMT, stromal, and the downregulated signature derived 
from the matched breast cancer primary tumors and multiorgan 
metastases by Siegel et al. (68) defined cluster 3. These data sug-
gest distinct changes in the metastatic setting when luminal/ER+ 
and basal-like tumors are compared.
FGFR4-associated signatures predict metastasis-free survival in 
visceral metastasis. We and others have previously shown that the 
PAM50 subtype predicts site of metastasis (69–71). Therefore, 
we sought to analyze the prognostic capacity of the 2 FGFR4 
signatures in 855 primary tumors with documented first site of 
relapse (69). The FGFR4-induced and -repressed signatures 
were strongly associated with risk of metastasis using multiple 
sites of first relapse (Figure 7F). Kaplan-Meier and Cox propor-
tional hazards model analyses detected strong significant asso-
ciations of FGFR4-induced signature with high risk for metas-
tasizing to the brain, lung, and liver (Figure 7, A, C, and E), but 
not to lymph nodes or bone (Figure 7, B and D). Likewise, high 
expression of the FGFR4-repressed signature predicted better 
prognosis in brain, lung, liver, and lymph node (Figure 7, A–C and 
E) but not in bone (Figure 7D).
Accounting for intrinsic subtype indicated that FGFR4- 
related signatures predicted distant recurrence in any subtype of 
luminal tumors (luminal A, luminal B, and HER2E), but not in 
basal-like or claudin-low tumors (Supplemental Figure 12). Next, 
using a multivariate analysis combining known clinical risk factors 
and dividing the tumors in basal-like and luminal groups, FGFR4- 
induced signature provided significant and independent prog-
nostic information in only the luminal group for brain, liver, and 
lung metastasis (Supplemental Figure 13A). Finally, the FGFR4- 
repressed signature predicted risk of distant recurrence only in 
luminal group tumors that relapse in brain (Supplemental Figure 
13B). Precisely why the FGFR4-induced signature shows predilec-
tion for the brain, liver, and lung requires further investigation, but 
we hypothesize that there could be microenvironmental features 
(either growth factors or specific cell-cell contacts) that facilitate 
growth of FGFR4+, HER2E tumors at these sites.
Discussion
The impact of genetics and genomics in breast cancer has 
improved our ability to efficiently predict the risk of recurrence 
and response to therapy, in a patient-specific and efficient man-
ner. Here, we developed 2 robust FGFR4-associated signatures 
using a HER2E/cHER2–/ER+ PDX model to explore the biolog-
ical significance of FGFR4 genomic signaling in breast cancer. 
The molecular profile obtained from this in vivo approach, the 
found strongest associations of FGFR4-induced signature with 
high risk of metastasizing to brain, lung, or liver but not to bone or 
lymph node. In agreement with an FGFR4–brain metastasis asso-
ciation, a genomic study of 20 paired primary and resected brain 
metastases also found the FGFR4 gene upregulated in 30% of 
brain metastases and ESR1 as the most recurrently downregulated 
gene (5). Thus, our study and those of others collectively suggest 
that the nongenetically defined FGFR4 signaling pathway plays 
an important role in the progression of luminal disease, predicts 
worse survival, and site-specific metastasis. Indeed, we show that 
many of these features can be disrupted using small molecules 
inhibiting FGFR4, for example, as we show using BLU9931. Thus, 
FGFR4 may be an attractive therapeutic target that could impact 
the metastatic setting and resistance to endocrine therapy.
Methods
Experimental details can be found in the Supplemental Methods.
Study approval. All human samples used here were either obtained 
from the public domain or were anonymized and deidentified (i.e., 
103 primary tumors and associated metastases); these latter samples 
were ruled as Not Human Subjects Research.
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The analysis of 696 expression modules revealed that besides 
proliferation and FGFR4 signatures, luminal-like metastases 
were associated with HER2E phenotype and luminal progeni-
tor features, and only a few modules related to immune signa-
tures including an M2 macrophage signature were more highly 
expressed in metastases.
Conversely, many fewer significant changes were found in 
basal-like metastatic tumors relative to primary, with the major 
changes being decreases in the vast majority of immune signa-
tures (B cells and T cells), signatures related to EMT, and stromal 
features, in agreement with previous studies (77–81). We did not 
observe any significant differences between primary and metasta-
ses in all proliferation-related scores or modules analyzed in bas-
al-like paired tumors (Figure 6E, Supplemental Table 9, and Sup-
plemental Figure 10B), contrasting with the luminal set (Figure 6, 
C and D). Thus, there are distinct changes in the immune micro-
environment according to tumor subtype, where in luminal-like 
tumors there is an increase in immunosuppressive macrophages, 
while in basal-like cancers there is a general downregulation of all 
immune cell processes.
Our findings also add context to prior studies where FGFR4 
plays a role in the biological response to endocrine therapies in 
ER+ breast tumors (82) and is enriched in endocrine-resistant 
ILC (41). In our study, we demonstrate the association between 
FGFR4 and the loss of luminal features, including ESR1 itself. 
Our established luminal cell lines overexpressing FGFR4 have 
lower ESR1 and LTS than controls cells. Similarly, in WHIM11 
PDX tumors, FGFR4-targeted inhibition resulted in higher 
ESR1 expression and ESR1-related signatures. In the clinical 
setting, luminal metastases also have lower levels of ESR1, 
PGR, and luminal-related signatures compared with their pri-
mary tumor counterparts. Together, these data led us to test 
FGFR4’s possible regulation of tumor growth independently 
of ESR1 and we found that overexpression of FGFR4 enables 
estrogen-independent growth (Supplemental Figure 6E). Thus, 
the increase in FGFR4 seen in our metastatic patients could 
be acquired as a long-term signaling adaptation. It becomes 
clear that patients analyzed in Levine and Meijer’s studies with 
higher FGFR4 mRNA levels may predict poor clinical benefit 
of endocrine therapy (41, 82). In fact, there are several ongo-
ing clinical trials using new pan-FGFR inhibitors, mostly in 
breast cancer patients with ER+/HER2–/FGFR1–3 amplifica-
tion (NCT03238196, NCT03344536) (83); the drugs used in 
these trials also impact FGFR4, and given that FGFR4 is rare-
ly amplified or mutated, the FGFR4+ (by mRNA and/or pro-
tein) patients are not being included. In clinical practice, both 
cHER2–/HER2E and cHER2+/HER2E breast cancers are likely 
to be FGFR4+, and thus may benefit from FGFR4 inhibitors. 
We suggest that high FGFR4 expression (by mRNA, protein, 
or by FGFR4-induced signature) could be considered as a pos-
sible inclusion criterion for patients to receive drugs targeting 
FGFR4. Last, we note that FGFR4 is not only highly expressed 
in cHER2–/HER2E tumors but also in cHER2+/HER2E and 
some basal-like tumors; thus, FGFR4 might also be a viable tar-
get in some basal-like tumors.
Finally, we demonstrated that these FGFR4-related signatures 
predicted not only survival, but also site-specific metastasis. We 
Address correspondence to: Charles M. Perou, Lineberger Com-
prehensive Cancer Center, University of North Carolina at 
Chapel Hill, Chapel Hill, North Carolina 27599, USA. Phone: 
919.843.5740; Email: cperou@med.unc.edu.
www.med.unc.edu/pathology/tpl), Translational Genomics Lab 
(https://unclineberger.org/tgl), and Flow Cytometry Core Facil-
ity (https://www.med.unc.edu/flowcytometry) at the University 
of North Carolina at Chapel Hill.
1. de Dueñas EM, et al. Prospective evaluation of the 
conversion rate in the receptor status between pri-
mary breast cancer and metastasis: results from 
the GEICAM 2009-03 ConvertHER study. Breast 
Cancer Res Treat. 2014;143(3):507–515.
2. Perou CM, et al. Molecular portraits of human 
breast tumours. Nature. 2000;406(6797):747–752.
3. Sørlie T, et al. Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with 
clinical implications. Proc Natl Acad Sci U S A. 
2001;98(19):10869–10874.
4. Cejalvo JM, et al. Intrinsic subtypes and gene 
expression profiles in primary and metastatic 
breast cancer. Cancer Res. 2017;77(9):2213–2221.
5. Priedigkeit N, et al. Intrinsic subtype switching 
and acquired ERBB2/HER2 amplifications and 
mutations in breast cancer brain metastases. 
JAMA Oncol. 2017;3(5):666–671.
6. Arteaga CL, Sliwkowski MX, Osborne CK, Perez 
EA, Puglisi F, Gianni L. Treatment of HER2- 
positive breast cancer: current status and future 
perspectives. Nat Rev Clin Oncol. 2011;9(1):16–32.
7. Slamon D, et al. Adjuvant trastuzumab in 
HER2-positive breast cancer. N Engl J Med. 
2011;365(14):1273–1283.
8. Prat A, et al. Research-based PAM50 subtype 
predictor identifies higher responses and 
improved survival outcomes in HER2-positive 
breast cancer in the NOAH study. Clin Cancer 
Res. 2014;20(2):511–521.
9. Basho RK, McArthur HL. Optimizing (neo)adju-
vant treatment of HER2-positive breast cancer. 
Ther Adv Med Oncol. 2018;10:1758835918775697.
10. Turner N, Grose R. Fibroblast growth factor 
signalling: from development to cancer. Nat Rev 
Cancer. 2010;10(2):116–129.
11. Beenken A, Mohammadi M. The FGF family: 
biology, pathophysiology and therapy. Nat Rev 
Drug Discov. 2009;8(3):235–253.
12. Ho HK, et al. Fibroblast growth factor receptor 
4 regulates proliferation, anti-apoptosis and 
alpha-fetoprotein secretion during hepatocellular 
carcinoma progression and represents a potential 
target for therapeutic intervention. J Hepatol. 
2009;50(1):118–127.
13. French DM, et al. Targeting FGFR4 inhibits 
hepatocellular carcinoma in preclinical mouse 
models. PLoS One. 2012;7(5):e36713.
14. Shah RN, Ibbitt JC, Alitalo K, Hurst HC. FGFR4 
overexpression in pancreatic cancer is mediated 
by an intronic enhancer activated by HNF1alpha. 
Oncogene. 2002;21(54):8251–8261.
15. Zaid TM, et al. Identification of FGFR4 as a 
potential therapeutic target for advanced-stage, 
high-grade serous ovarian cancer. Clin Cancer 
Res. 2013;19(4):809–820.
16. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, 
Ullrich A. Involvement of the FGFR4 Arg388 
allele in head and neck squamous cell carcinoma. 
Int J Cancer. 2004;111(2):213–217.
17. Spinola M, et al. FGFR4 Gly388Arg polymor-
phism and prognosis of breast and colorectal 
cancer. Oncol Rep. 2005;14(2):415–419.
18. Wang J, Stockton DW, Ittmann M. The fibroblast 
growth factor receptor-4 Arg388 allele is associated 
with prostate cancer initiation and progression. Clin 
Cancer Res. 2004;10(18 pt 1):6169–6178.
19. Bange J, et al. Cancer progression and tumor cell 
motility are associated with the FGFR4 Arg(388) 
allele. Cancer Res. 2002;62(3):840–847.
20. Huang KL, et al. Proteogenomic integration 
reveals therapeutic targets in breast cancer 
xenografts. Nat Commun. 2017;8:14864.
21. Li S, et al. Endocrine-therapy-resistant ESR1 
variants revealed by genomic characterization 
of breast-cancer-derived xenografts. Cell Rep. 
2013;4(6):1116–1130.
22. Hagel M, et al. First selective small molecule 
inhibitor of FGFR4 for the treatment of hepatocel-
lular carcinomas with an activated FGFR4 signal-
ing pathway. Cancer Discov. 2015;5(4):424–437.
23. Medina PJ, Goodin S. Lapatinib: a dual inhibitor 
of human epidermal growth factor receptor tyro-
sine kinases. Clin Ther. 2008;30(8):1426–1447.
24. Prat A, et al. Prognostic value of intrinsic subtypes 
in hormone receptor-positive metastatic breast 
cancer treated with letrozole with or without lapa-
tinib. JAMA Oncol. 2016;2(10):1287–1294.
25. Usary J, Darr DB, Pfefferle AD, Perou CM. Over-
view of genetically engineered mouse models 
of distinct breast cancer subtypes. Curr Protoc 
Pharmacol. 2016;72:14.38.1–14.38.11.
26. Roberts PJ, et al. Combined PI3K/mTOR and 
MEK inhibition provides broad antitumor activ-
ity in faithful murine cancer models. Clin Cancer 
Res. 2012;18(19):5290–5303.
27. Lim E, et al. Aberrant luminal progenitors as 
the candidate target population for basal tumor 
development in BRCA1 mutation carriers. Nat 
Med. 2009;15(8):907–913.
28. Prat A, Perou CM. Mammary development meets 
cancer genomics. Nat Med. 2009;15(8):842–844.
29. Prat A, et al. Phenotypic and molecular charac-
terization of the claudin-low intrinsic subtype of 
breast cancer. Breast Cancer Res. 2010;12(5):R68.
30. Parker JS, et al. Supervised risk predictor of breast 
cancer based on intrinsic subtypes. J Clin Oncol. 
2009;27(8):1160–1167.
31. Tusher VG, Tibshirani R, Chu G. Significance 
analysis of microarrays applied to the ionizing 
radiation response. Proc Natl Acad Sci U S A. 
2001;98(9):5116–5121.
32. Efron B, Tibshirani R, Storey JD, Tusher V. 
Empirical Bayes analysis of a microarray experi-
ment. J Am Stat Assoc. 2001;96(456):1151–1160.
33. Efron B, Tibshirani R. Empirical bayes methods 
and false discovery rates for microarrays. Genet 
Epidemiol. 2002;23(1):70–86.
34. Subramanian A, et al. Gene set enrichment analy-
sis: a knowledge-based approach for interpreting 
genome-wide expression profiles. Proc Natl Acad 
Sci U S A. 2005;102(43):15545–15550.
35. Fan C, et al. Building prognostic models for 
breast cancer patients using clinical variables and 
hundreds of gene expression signatures. BMC 
Med Genomics. 2011;4:3.
36. Wallden B, et al. Development and verification of 
the PAM50-based Prosigna breast cancer gene 
signature assay. BMC Med Genomics. 2015;8:54.
37. Duncan JS, et al. Dynamic reprogramming of 
the kinome in response to targeted MEK inhi-
bition in triple-negative breast cancer. Cell. 
2012;149(2):307–321.
38. Daub H, et al. Kinase-selective enrichment 
enables quantitative phosphoproteomics of 
the kinome across the cell cycle. Mol Cell. 
2008;31(3):438–448.
39. Bantscheff M, et al. Quantitative chemical 
proteomics reveals mechanisms of action of 
clinical ABL kinase inhibitors. Nat Biotechnol. 
2007;25(9):1035–1044.
 40. Roidl A, et al. The FGFR4 Y367C mutant is a 
dominant oncogene in MDA-MB453 breast can-
cer cells. Oncogene. 2010;29(10):1543–1552.
41. Levine KM, et al. FGFR4 overexpression and 
hotspot mutations in metastatic ER+ breast 
cancer are enriched in the lobular subtype. 
NPJ Breast Cancer. 2019;5:19.
42. McFarland JM, et al. Improved estimation of can-
cer dependencies from large-scale RNAi screens 
using model-based normalization and data inte-
gration. Nat Commun. 2018;9(1):4610.
43. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi 
M, Mesirov JP, Tamayo P. The Molecular Sig-
natures Database (MSigDB) hallmark gene set 
collection. Cell Syst. 2015;1(6):417–425.
44. Liberzon A, Subramanian A, Pinchback R, 
Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molec-
ular signatures database (MSigDB) 3.0. Bioinfor-
matics. 2011;27(12):1739–1740.
45. Tirosh I, et al. Dissecting the multicellular eco-
system of metastatic melanoma by single-cell 
RNA-seq. Science. 2016;352(6282):189–196.
46. Kim S, Lee K, Choi JH, Ringstad N, Dynlacht 
BD. Nek2 activation of Kif24 ensures cilium 
disassembly during the cell cycle. Nat Commun. 
2015;6:8087.
47. Pugacheva EN, Jablonski SA, Hartman TR, 
Henske EP, Golemis EA. HEF1-dependent Aurora 
A activation induces disassembly of the primary 
cilium. Cell. 2007;129(7):1351–1363.
48. Jacoby M, et al. INPP5E mutations cause primary 
cilium signaling defects, ciliary instability and 
ciliopathies in human and mouse. Nat Genet. 
2009;41(9):1027–1031.
49. Ciriello G, et al. Comprehensive molecular 
portraits of invasive lobular breast cancer. Cell. 
2015;163(2):506–519.
50. Cross SS, Hamdy FC, Deloulme JC, Rehman I. 
Expression of S100 proteins in normal human 
tissues and common cancers using tissue 
microarrays: S100A6, S100A8, S100A9 and 
S100A11 are all overexpressed in common can-
cers. Histopathology. 2005;46(3):256–269.
51. Bao YI, Wang A, Mo J. S100A8/A9 is associated 
with estrogen receptor loss in breast cancer. 
Oncol Lett. 2016;11(3):1936–1942.
52. Rodriguez-Barrueco R, et al. Inhibition of the 
autocrine IL-6-JAK2-STAT3-calprotectin axis as 
targeted therapy for HR-/HER2+ breast cancers. 
Genes Dev. 2015;29(15):1631–1648.
53. Bergenfelz C, et al. S100A9 expressed in ER(-)
PgR(-) breast cancers induces inflammatory cyto-
kines and is associated with an impaired overall 
survival. Br J Cancer. 2015;113(8):1234–1243.
54. Welte T, et al. Oncogenic mTOR signalling 
recruits myeloid-derived suppressor cells 
to promote tumour initiation. Nat Cell Biol. 
2016;18(6):632–644.
55. Gebhardt C, Németh J, Angel P, Hess J. S100A8 
and S100A9 in inflammation and cancer. 
Biochem Pharmacol. 2006;72(11):1622–1631.
56. Steinbakk M, Naess-Andresen CF, Lingaas E, 
Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial 
actions of calcium binding leucocyte L1 protein, 
calprotectin. Lancet. 1990;336(8718):763–765.
57. D’Amato NC, et al. A TDO2-AhR signaling axis 
facilitates anoikis resistance and metastasis 
in triple-negative breast cancer. Cancer Res. 
2015;75(21):4651–4664.
58. Novikov O, et al. An aryl hydrocarbon receptor- 
mediated amplification loop that enforces cell 
migration in ER-/PR-/Her2- human breast cancer
cells. Mol Pharmacol. 2016;90(5):674–688.
59. Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. 
An integrated genomics approach identifies 
drivers of proliferation in luminal-subtype human 
breast cancer. Nat Genet. 2014;46(10):1051–1059.
 60. Rőszer T. Understanding the mysterious M2 
macrophage through activation markers and 
effector mechanisms. Mediators Inflamm. 
2015;2015:816460.
61. Duluc D, et al. Tumor-associated leukemia 
inhibitory factor and IL-6 skew monocyte differ-
entiation into tumor-associated macrophage-like 
cells. Blood. 2007;110(13):4319–4330.
62. Georgoudaki AM, et al. Reprogramming 
tumor-associated macrophages by antibody 
targeting inhibits cancer progression and metas-
tasis. Cell Rep. 2016;15(9):2000–2011.
63. Razavi P, et al. The genomic landscape of endo-
crine-resistant advanced breast cancers. Cancer 
Cell. 2018;34(3):427–438.e6.
64. Hoadley KA, et al. Cell-of-origin patterns 
dominate the molecular classification of 
10,000 tumors from 33 types of cancer. Cell. 
2018;173(2):291–304.e6.
65. Lefebvre C, et al. Mutational profile of metastatic 
breast cancers: a retrospective analysis. PLoS 
Med. 2016;13(12):e1002201.
66. Forbes SA, et al. COSMIC: somatic cancer 
genetics at high-resolution. Nucleic Acids Res. 
2017;45(D1):D777–D783.
67. Catalogue of somatic mutations in cancer 
(COSMIC). https://www.cancer.sanger.ac.uk. 
Updated April 7, 2020. Accessed June 26, 2020.
68. Siegel MB, et al. Integrated RNA and DNA 
sequencing reveals early drivers of metastatic 
breast cancer. J Clin Invest. 2018;128(4):1371–1383.
69. Harrell JC, et al. Genomic analysis identifies 
unique signatures predictive of brain, lung, 
and liver relapse. Breast Cancer Res Treat. 
2012;132(2):523–535.
70. Smid M, et al. Subtypes of breast cancer 
show preferential site of relapse. Cancer Res. 
2008;68(9):3108–3114.
71. Sihto H, et al. Breast cancer biological subtypes 
and protein expression predict for the preferen-
tial distant metastasis sites: a nationwide cohort 
study. Breast Cancer Res. 2011;13(5):R87.
72. Gao G, Goldfarb M. Heparin can activate a receptor 
tyrosine kinase. EMBO J. 1995;14(10):2183–2190.
73. Loo BM, Kreuger J, Jalkanen M, Lindahl U, Salmi-
virta M. Binding of heparin/heparan sulfate to 
fibroblast growth factor receptor 4. J Biol Chem. 
2001;276(20):16868–16876.
74. Cavallaro U, Niedermeyer J, Fuxa M, Christofori 
G. N-CAM modulates tumour-cell adhesion to 
matrix by inducing FGF-receptor signalling. 
Nat Cell Biol. 2001;3(7):650–657.
75. Pan H, et al. 20-Year risks of breast-cancer recur-
rence after stopping endocrine therapy at 5 years. 
N Engl J Med. 2017;377(19):1836–1846.
76. Kennecke H, et al. Metastatic behavior 
of breast cancer subtypes. J Clin Oncol. 
2010;28(20):3271–3277.
77. Saraiva DP, Guadalupe Cabral M, Jacinto A,
Braga S. How many diseases is triple nega-
tive breast cancer: the protagonism of the 
immune microenvironment. ESMO Open. 
2017;2(4):e000208.
78. Ogiya R, et al. Comparison of tumor-infiltrating 
lymphocytes between primary and metastatic 
tumors in breast cancer patients. Cancer Sci. 
2016;107(12):1730–1735.
79. Sobottka B, Pestalozzi B, Fink D, Moch H, Varga 
Z. Similar lymphocytic infiltration pattern in 
primary breast cancer and their correspond-
ing distant metastases. Oncoimmunology. 
2016;5(6):e1153208.
80. Szekely B, et al. Immunological differences 
between primary and metastatic breast cancer. 
Ann Oncol. 2018;29(11):2232–2239.
81. Zhu L, et al. Metastatic breast cancers have 
reduced immune cell recruitment but har-
bor increased macrophages relative to their 
matched primary tumors. J Immunother Cancer. 
2019;7(1):265.
82. Meijer D, Sieuwerts AM, Look MP, van Agthoven 
T, Foekens JA, Dorssers LC. Fibroblast growth 
factor receptor 4 predicts failure on tamoxifen 
therapy in patients with recurrent breast cancer. 
Endocr Relat Cancer. 2008;15(1):101–111.
83. Clinical Trials - A service of the US National Insti-
tutes of Health. http://clinicaltrialsgov. 2018. 
NCT03238196, NCT03344536.
 84. Mermel CH, Schumacher SE, Hill B, Meyer-
son ML, Beroukhim R, Getz G. GISTIC2.0 
facilitates sensitive and confident localization 
of the targets of focal somatic copy-number 
alteration in human cancers. Genome Biol. 
2011;12(4):R41.
85. Cancer Genome Atlas Network. Comprehensive 
molecular portraits of human breast tumours. 
Nature. 2012;490(7418):61–70.
